Comparative Analysis of Autografting in Chronic Myelogenous Leukemia: Effects of Priming Regimen and Marrow or Blood Origin of Stem Cells
Open Access
- 1 September 1998
- journal article
- Published by American Society of Hematology in Blood
- Vol. 92 (5) , 1820-1831
- https://doi.org/10.1182/blood.v92.5.1820
Abstract
The aims of this study were (1) to evaluate the effect of intermediate (cyclophosphamide alone) or intensive (mitoxantrone, cytosine arabinoside, cyclophosphamide) priming on the cytogenetic response in mobilized bone marrow (BM) or peripheral blood (PB) progenitors in patients with chronic myelogenous leukemia (CML), (2) to determine the incidence of cytogenetic remissions after mobilized progenitor transplantation in CML, and (3) to determine the effect of in vivo priming on the ability to select Philadelphia chromosome–negative (Ph-negative) CD34+HLA-DR− cells from mobilized BM or PB in quantities sufficient for transplantation. Between February 1994 and March 1997, 44 patients were enrolled in three sequential protocols. Although the duration of neutropenia after only cyclophosphamide mobilization was shorter, clinical morbidity for the intermediate and intensive priming protocols was similar. Cytogenetic responses in mobilized PB progenitors were similar after mobilization with either intermediate or intensive chemotherapy. The degree of Ph negativity in the mobilized product correlated with disease stage at the time of mobilization (early chronic phase [ECP] > late CP > accelerated phase). Cytogenetic responses after transplantation with mobilized progenitors obtained after the different regimens were similar. The cytogenetic status of the graft predicted the cytogenetic status of marrow obtained 3 weeks after transplantation whereas cytogenetic responses 3, 6, and 12 months after transplantation correlated with the number of BCR/ABL–negative CD34+HLA-DR−cells, but not the number of Ph-negative metaphases in the graft. In patients with ECP CML, mobilized PB collections yielded significantly more CD34+HLA-DR− cells than from steady state or mobilized BM. CD34+HLA-DR− cells were Ph negative and polyclonal (X-chromosome inactivation) in the majority of ECP CML patients, before and after mobilization and irrespective of the mobilization regimen. Because infusion of large numbers of Ph-negative CD34+HLA-DR− cells predicted superior outcome after transplantation, approaches in which CD34+HLA-DR− cells are selected from mobilized PB may result in longer lasting and clinically significant cytogenetic responses after transplantation. © 1998 by The American Society of Hematology.Keywords
This publication has 52 references indexed in Scilit:
- Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological controlBritish Journal of Haematology, 1997
- Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia‐negative peripheral blood stem cellsBritish Journal of Haematology, 1997
- Demonstration of developing myelodysplasia/acute myeloid leukaemia in haematologically normal patients after high‐dose chemotherapy and autologous bone marrow transplantation using X‐chromosome inactivation patternsBritish Journal of Haematology, 1996
- Idarubicin, Intermediate-Dose Cytarabine, Etoposide, and Granulocyte-Colony-Stimulating Factor Are Able to Recruit CD34+/HLA-DR-Cells During Early Hematopoietic Recovery in Accelerated and Chronic Phases of Chronic Myeloid LeukemiaJournal of Hematotherapy, 1994
- Selective overshoot of ph‐negative blood hemopoietic cells after intensive idarubicin‐containing regimen and their repopulating capacity after reinfusionThe International Journal of Cell Cloning, 1993
- bcr/abl mRNA DETECTION FOLLOWING BONE MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIATransplantation, 1991
- Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma.The Journal of Experimental Medicine, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemiaNature, 1983
- Long-Term Marrow Culture Reveals Chromosomally Normal Hematopoietic Progenitor Cells in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1983